Senju Pharmaceutical patented a method for treating retinal epithelium and nerve diseases by administering laminin 511 or its fragments along with retinal pigment epithelial cells or nerve cells. The technique aims to address conditions like retinitis pigmentosa, macular degeneration, and glaucoma. GlobalData’s report on Senju Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Senju Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Senju Pharmaceutical's grant share as of April 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of retinal and nerve diseases using laminin 511
A recently granted patent (Publication Number: US11918630B2) discloses a method for treating diseases, disorders, or conditions of a nerve that require cell transplantation in a subject. The method involves administering either laminin 511 or its fragments along with nerve cells or retinal pigment epithelial cells to the subject. The conditions that can be treated using this method include retinitis pigmentosa, macular degeneration, Stargardt disease, glaucoma, or optic neuropathy.
Furthermore, the patent claims specify that the nerve cell is administered to the subject in some instances, while in others, the specific agent used is the laminin 511-E8 fragment. This method presents a novel approach to treating nerve-related conditions by utilizing specific agents in combination with nerve cells or retinal pigment epithelial cells. The inclusion of laminin 511 or its fragments in the treatment process highlights the potential for targeted and effective therapies for a range of nerve-related diseases and disorders.
To know more about GlobalData’s detailed insights on Senju Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.